ScoreComparison
Why is Verrica Pharmaceuticals, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -3.09% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -10.33
2
With a growth in Net Sales of 145.35%, the company declared Very Positive results in Jun 25
- NET SALES(HY) Higher at USD 16.14 MM
- ROCE(HY) Highest at 0%
- RAW MATERIAL COST(Y) Fallen by -7.43% (YoY)
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -48.34%, its profits have risen by 22.4%
4
High Institutional Holdings at 42.9%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -48.34% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Verrica Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Verrica Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Verrica Pharmaceuticals, Inc.
-28.64%
-0.05
853.52%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
73.45%
EBIT Growth (5y)
-3.09%
EBIT to Interest (avg)
-10.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.32
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
42.90%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-3.05
EV to EBIT
-1.25
EV to EBITDA
-1.28
EV to Capital Employed
-9.91
EV to Sales
9.52
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend25What is working for the Company
NET SALES(HY)
Higher at USD 16.14 MM
ROCE(HY)
Highest at 0%
RAW MATERIAL COST(Y)
Fallen by -7.43% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -134.39 %
OPERATING PROFIT(Q)
Highest at USD 1.71 MM
PRE-TAX PROFIT(Q)
Highest at USD -0.39 MM
NET PROFIT(Q)
Highest at USD -0.39 MM
EPS(Q)
Highest at USD 0.02
-2What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 44.99 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 1.07 times
Here's what is working for Verrica Pharmaceuticals, Inc.
Net Sales
At USD 16.14 MM has Grown at 79.28%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Sales
Higher at USD 16.14 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Operating Profit
Highest at USD 1.71 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -0.39 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -0.39 MM has Grown at 97.71%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -0.39 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Profit
At USD -0.39 MM has Grown at 97.71%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.02
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -134.39 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -7.43% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Verrica Pharmaceuticals, Inc.
Cash and Eqv
Lowest at USD 44.99 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio
Lowest at 1.07 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
